{"id":382688,"date":"2020-11-17T07:33:13","date_gmt":"2020-11-17T12:33:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=382688"},"modified":"2020-11-17T07:33:13","modified_gmt":"2020-11-17T12:33:13","slug":"salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/","title":{"rendered":"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium"},"content":{"rendered":"
\n

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc.<\/a>\u00a0(Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.\u2019s Virtual Healthcare Symposium on Thursday, November 19, 2020.<\/p>\n

Mr. Arthur will host virtual one-on-one meetings with investors registered to attend the conference to discuss Salarius\u2019 business, recent achievements, and anticipated clinical milestones. The Company\u2019s lead drug candidate, seclidemstat, is an oral medication that inhibits lysine-specific demethylase 1 (LSD1), an enzyme that is over-produced in some cancers and can promote disease progression. Seclidemstat is being studied in two ongoing Phase 1\/2 clinical trials \u2014 the first, in patients with relapsed or refractory Ewing sarcoma, a deadly bone and soft tissue cancer primarily diagnosed in children and young adults, and the second, in patients with advanced solid tumors (AST). Early clinical data suggests that that patients can be treated at dose levels that produce drug concentrations similar to concentrations where seclidemstat showed anti-tumor activity in preclinical models.<\/p>\n

Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions. Target lesions generally represent a patient\u2019s largest measurable tumors.<\/p>\n

For questions and inquiries regarding the conference or to register for a one-on-one meeting, please contact a registered A.G.P. representative or email A.G.P. Events at AGPEVENTS@ALLIANCEG.COM<\/a>.<\/p>\n

\n About\u00a0Salarius Pharmaceuticals<\/strong>
\n
Salarius Pharmaceuticals, Inc.\u00a0is a clinical-stage biopharmaceutical company developing cancer therapies for patients that need them the most. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1\/2 clinical trial for relapsed\/refractory Ewing\u00a0sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the\u00a0U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1\/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius previously disclosed that a refractory Ewing sarcoma patient treated with seclidemstat for six months demonstrated a reduction of over 80% in prospectively defined target lesions. Target lesions generally represent a patient\u2019s largest measurable tumors. However, at eight weeks, an increase in non-target lesions resulted in an overall patient classification of progressive disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST). Salarius has received financial support from the\u00a0National Pediatric Cancer Foundation\u00a0to advance the\u00a0Ewing sarcoma clinical program and was also the recipient of an\u00a0$18.7 million\u00a0Product Development Award from the\u00a0Cancer Prevention and Research Institute of Texas\u00a0(CPRIT). For more information, please visit salariuspharma.com<\/a> or follow the Company on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

\n Forward-Looking Statements\u00a0<\/strong>
\n
This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as \u201cwill,\u201d \u201ccould,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201ctarget,\u201d and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, the potential of seclidemstat as a potential treatment for Ewing-related sarcomas; the ability of seclidemstat to demonstrate drug activity; the ability of and degree to which seclidemstat could have a significant impact on the treatment of Ewing sarcoma, as well as other sarcomas with related Ewing sarcoma biology; and the safety profile of seclidemstat in any indication. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the ability of Salarius to raise additional capital to meet its business operational needs and to achieve its business objectives and strategy; Salarius\u2019 ability to project future capital needs and cash utilization; available sources of cash, including from CPRIT and its equity line; future clinical trial results; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius\u2019 intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions which may impact the ability of Salarius access capital under its equity line; the possibility of unexpected expenses or other uses of Salarius\u2019 cash resources; and other risks described in Salarius\u2019 filings with the Securities and Exchange Commission, including those under the heading \u201cRisk Factors.\u201d The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management\u2019s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.<\/p>\n

\n Contact<\/strong>
\n
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA\/Miriam Miller (investors)
(212) 375-2664 \/ 2694
mmcenroe@tiberend.com<\/a>
mmiller@tiberend.com<\/u><\/p>\n

Johanna Bennett (media)
(212)\u00a0375-2686\u00a0
jbennett@tiberend.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc.\u00a0(Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.\u2019s Virtual Healthcare Symposium on Thursday, November 19, 2020. Mr. Arthur will host virtual one-on-one meetings with investors registered to attend the conference to discuss Salarius\u2019 business, recent achievements, and anticipated clinical milestones. The Company\u2019s lead drug candidate, seclidemstat, is an oral medication that inhibits lysine-specific demethylase 1 (LSD1), an enzyme that is over-produced in some cancers and can promote disease progression. Seclidemstat is being studied in two ongoing Phase 1\/2 clinical trials \u2014 the first, in patients with relapsed … <\/p>\n

Continue reading “Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-382688","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSalarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc.\u00a0(Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.\u2019s Virtual Healthcare Symposium on Thursday, November 19, 2020. Mr. Arthur will host virtual one-on-one meetings with investors registered to attend the conference to discuss Salarius\u2019 business, recent achievements, and anticipated clinical milestones. The Company\u2019s lead drug candidate, seclidemstat, is an oral medication that inhibits lysine-specific demethylase 1 (LSD1), an enzyme that is over-produced in some cancers and can promote disease progression. Seclidemstat is being studied in two ongoing Phase 1\/2 clinical trials \u2014 the first, in patients with relapsed … Continue reading "Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T12:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium\",\"datePublished\":\"2020-11-17T12:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/\"},\"wordCount\":895,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/\",\"name\":\"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=\",\"datePublished\":\"2020-11-17T12:33:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium - Market Newsdesk","og_description":"HOUSTON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc.\u00a0(Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors and other cancers, today announced its chief executive officer, David Arthur, will participate in A.G.P.\u2019s Virtual Healthcare Symposium on Thursday, November 19, 2020. Mr. Arthur will host virtual one-on-one meetings with investors registered to attend the conference to discuss Salarius\u2019 business, recent achievements, and anticipated clinical milestones. The Company\u2019s lead drug candidate, seclidemstat, is an oral medication that inhibits lysine-specific demethylase 1 (LSD1), an enzyme that is over-produced in some cancers and can promote disease progression. Seclidemstat is being studied in two ongoing Phase 1\/2 clinical trials \u2014 the first, in patients with relapsed … Continue reading \"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T12:33:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium","datePublished":"2020-11-17T12:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/"},"wordCount":895,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/","name":"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=","datePublished":"2020-11-17T12:33:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NzI4NSMzODMwNjUzIzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-to-participate-in-a-g-p-s-virtual-healthcare-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals to Participate in A.G.P.\u2019s Virtual Healthcare Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=382688"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/382688\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=382688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=382688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=382688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}